|
EA202191432A1
(ru)
|
2018-11-22 |
2021-10-14 |
Цилу Регор Терапьютикс Инк. |
Агонисты glp-1r и их применения
|
|
AU2020256647B2
(en)
*
|
2019-04-12 |
2025-07-31 |
Qilu Regor Therapeutics Inc. |
GLP-1R agonists and uses thereof
|
|
TWI751585B
(zh)
|
2019-06-28 |
2022-01-01 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
CR20220178A
(es)
|
2019-10-25 |
2022-06-15 |
Gilead Sciences Inc |
Compuestos moduladores de glp-1r
|
|
EP4069686B1
(en)
*
|
2019-12-02 |
2025-01-22 |
Hyundai Pharm Co., Ltd. |
Glp-1 receptor agonist
|
|
SI4097097T1
(sl)
|
2020-01-29 |
2025-04-30 |
Gilead Sciences, Inc. |
Spojine, ki modulirajo glp-1r
|
|
PT4097099T
(pt)
|
2020-02-07 |
2024-07-19 |
Gasherbrum Bio Inc |
Agonistas heterocíclicos de glp-1
|
|
MX2022011349A
(es)
*
|
2020-03-18 |
2022-11-10 |
Lg Chemical Ltd |
Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
|
|
TW202144340A
(zh)
*
|
2020-04-03 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
|
|
WO2021219019A1
(en)
|
2020-04-29 |
2021-11-04 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
PE20231181A1
(es)
|
2020-08-06 |
2023-08-11 |
Gasherbrum Bio Inc |
Agonistas del glp-1 heterociclicos
|
|
JP2023538949A
(ja)
|
2020-08-28 |
2023-09-12 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環glp-1アゴニスト
|
|
WO2022052958A1
(en)
|
2020-09-10 |
2022-03-17 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
EP4247804A1
(en)
|
2020-11-20 |
2023-09-27 |
Gilead Sciences, Inc. |
Polyheterocyclic glp-1 r modulating compounds
|
|
WO2022111624A1
(zh)
*
|
2020-11-27 |
2022-06-02 |
深圳信立泰药业股份有限公司 |
一种苯并咪唑类衍生物及其制备方法和医药用途
|
|
EP4304711A1
(en)
|
2021-03-11 |
2024-01-17 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
US12180197B2
(en)
|
2021-03-11 |
2024-12-31 |
Gilead Sciences, Inc. |
GLP-1R modulating compounds
|
|
EP4317145A4
(en)
|
2021-03-24 |
2025-03-12 |
Shionogi & Co., Ltd |
Pharmaceutical composition containing glp-1 receptor agonist having fused ring
|
|
US20240300928A1
(en)
*
|
2021-04-08 |
2024-09-12 |
Lg Chem, Ltd. |
Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
|
|
LT4271672T
(lt)
|
2021-04-21 |
2026-03-10 |
Gilead Sciences, Inc. |
Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
|
|
TWI843104B
(zh)
|
2021-05-20 |
2024-05-21 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
CN117098758A
(zh)
|
2021-06-24 |
2023-11-21 |
杭州中美华东制药有限公司 |
Glp-1受体激动剂及其组合物和用途
|
|
CN113480534B
(zh)
*
|
2021-07-23 |
2022-05-13 |
广州必贝特医药股份有限公司 |
苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
|
|
KR20240053617A
(ko)
|
2021-08-30 |
2024-04-24 |
민드랭크 에이아이 리미티드 |
Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
|
|
KR20240056719A
(ko)
|
2021-09-08 |
2024-04-30 |
시오노기 앤드 컴파니, 리미티드 |
항비만 작용이 관여하는 질환의 예방 및 치료용 의약
|
|
SI4408840T1
(sl)
|
2021-09-27 |
2025-12-31 |
Terns Pharmaceuticals, Inc. |
Benzimidazolne karboksilne kisline kot agonisti GLP-1R
|
|
WO2023057427A1
(en)
|
2021-10-05 |
2023-04-13 |
Astrazeneca Ab |
Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
|
|
US20250236627A1
(en)
|
2021-10-05 |
2025-07-24 |
Astrazeneca Ab |
Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
|
|
WO2023057429A1
(en)
|
2021-10-05 |
2023-04-13 |
Astrazeneca Ab |
Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
|
|
US12024507B2
(en)
|
2021-10-25 |
2024-07-02 |
Terns Pharmaceuticals, Inc. |
Compounds as GLP-1R agonists
|
|
US20250042882A1
(en)
|
2021-12-16 |
2025-02-06 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
US20250066338A1
(en)
|
2021-12-16 |
2025-02-27 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
AU2023224854A1
(en)
|
2022-02-23 |
2024-10-03 |
Terns Pharmaceuticals, Inc. |
Compounds as glp-1r agonists
|
|
CN116574092B
(zh)
*
|
2022-05-20 |
2024-08-20 |
成都地奥九泓制药厂 |
苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
|
|
CN119923395A
(zh)
*
|
2022-07-27 |
2025-05-02 |
卡莫特医疗有限公司 |
N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法
|
|
CN119907794A
(zh)
|
2022-09-22 |
2025-04-29 |
盐野义制药株式会社 |
具有glp-1受体激动剂作用的稠环化合物
|
|
WO2024102625A1
(en)
|
2022-11-11 |
2024-05-16 |
Eli Lilly And Company |
Glucagon-like peptide 1 receptor agonists
|
|
CR20250178A
(es)
|
2022-11-16 |
2025-06-06 |
Lilly Co Eli |
Agonistas del receptor del péptido-1 similar al glucagón
|
|
JP2026501161A
(ja)
*
|
2022-12-13 |
2026-01-14 |
杭州中美華東製薬有限公司 |
Glp-1受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用
|
|
KR20250168210A
(ko)
|
2023-02-16 |
2025-12-02 |
가셔브룸 바이오, 인크. |
헤테로시클릭 glp-1 효능제
|
|
PE20252787A1
(es)
|
2023-04-07 |
2025-12-22 |
Terns Pharmaceuticals Inc |
Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
|
|
EP4777197A2
(en)
|
2023-09-14 |
2026-07-22 |
Ascletis Pharma (China) Co., Limited |
Glp-1r agonist and therapeutic method thereof
|
|
AU2024380885A1
(en)
*
|
2023-11-13 |
2026-05-14 |
Aspen Neuroscience, Inc. |
Methods of predicting characteristics of differentiated neuronal cells
|
|
WO2025109387A1
(en)
|
2023-11-24 |
2025-05-30 |
Ascletis Pharma (China) Co., Limited |
Glp-1r agonist and therapeutic method thereof
|
|
WO2025158275A1
(en)
|
2024-01-24 |
2025-07-31 |
Pfizer Inc. |
Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
|
|
TW202600132A
(zh)
|
2024-03-08 |
2026-01-01 |
美商安尼波那生物公司 |
用於治療肥胖症及提高減重之方法
|
|
KR20260038229A
(ko)
|
2024-09-11 |
2026-03-18 |
한미약품 주식회사 |
Glp-1 수용체 작용제 및 이의 용도
|